Top

Supportive Care in Cancer

Published in:

01-10-2015 | Original Article

Development and validation of the Lymphedema Symptom and Intensity Survey-Arm

Authors: Sheila H. Ridner, Mary S. Dietrich

Published in: Supportive Care in Cancer | Issue 10/2015

Abstract

Purpose

The purpose of this instrument development project was to create a self-report tool to evaluate arm lymphedema and associated symptoms in breast cancer survivors.

Methods

The Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A) was developed and tested in three phases: phase 1—literature review and expert panel; phase 2—preliminary validation; and phase 3—final validation.

Results

Phase 1: The most common symptoms experienced by breast cancer survivors with lymphedema were identified. A 52-item scale was developed. Phase 2: 128 community-dwelling breast cancer survivors (64 with lymphedema, 64 without lymphedema) completed the LSIDS-A. Feedback from the participants was that the format was “clear” and “made sense”; therefore, the response structure was left intact. Sixteen items were deleted leaving a 36-item revised instrument. Phase 3: Subsequent testing in a total sample of 236 breast cancer survivors with lymphedema was undertaken. The Cronbach’s alpha reliability values for the overall intensity and distress scores were 0.93 and 0.94, respectively. The Kuder-Richardson values ranged from 0.66 to 0.92. Divergent validity evaluated against Marlowe-Crowne Social Desirebility Scale overall was acceptable (intensity, r _s = 0.08; distress, r _s = −0.12). Convergent validity was acceptable as tested with multiple instruments (e.g., Functional Assessment of Cancer Therapy-Breast +4, overall intensity r _s = −0.44, overall distress r _s = −.48)

Conclusions

The 30-item LSIDS-A is a valid and reliable instrument that can be used to assess arm lymphedema and its associated symptoms.

Bulley C, Coutts F, Blyth C, Jack W, Chetty U, Barber M, Tan CW (2014) A Morbidity Screening Tool for identifying fatigue, pain, upper limb dysfunction and lymphedema after breast cancer treatment: a validity study. Eur J Oncol Nurs 18(2):218–227. doi:10.1016/j.ejon.2013.10.006 CrossRefPubMed

Deng J, Ridner SH, Murphy BA, Dietrich MS (2012) Preliminary development of a lymphedema symptom assessment scale for patients with head and neck cancer. Support Care Cancer 20(8):1911–1918. doi:10.1007/s00520-011-1294-6 CrossRefPubMed

Ridner SH, Dietrich MS, Kidd N (2011) Breast cancer treatment-related lymphedema self-care: education, practices, symptoms, and quality of life. Support Care Cancer 19(5):631–637. doi:10.1007/s00520-010-0870-5 CrossRefPubMed

Weissleder H, Schuchhardt C (2008) Lymphedema: Diagnosis and therapy, 4th edn. Viavital, Berlin

Szuba A, Rockson SG (1998) Lymphedema: Classification, diagnosis and therapy. Vasc Med 3(2):145–156CrossRefPubMed

Ridner SH, Fu MR, Wanchai A, Stewart BR, Armer JM, Cormier JN (2012) Self-management of Lymphedema: A systematic review of the literature from 2004 to 2011. Nurs Res 61(4):291–299. doi:10.1097/NNR.0b013e31824f82b2 CrossRefPubMed

International Society of Lymphology (2003) The Diagnosis and Treatment of Peripheral Lymphedema: Consensus document of the International Society of Lymphology. Lymphology 36:84–91

Ridner SH (2005) Quality of life and a symptom cluster associated with breast cancer treatment-related lymphedema. Support Care Cancer 13(11):904–911. doi:10.1007/s00520-005-0810-y CrossRefPubMed

Ridner SH, Montgomery LD, Hepworth JT, Stewart BR, Armer JM (2007) Comparison of upper limb volume measurement techniques and arm symptoms between healthy volunteers and individuals with known lymphedema. Lymphology 40(1):35–46PubMed

10.

Woods M (1993) Patients' perceptions of breast-cancer-related lymphoedema. Eur J Cancer Care (Engl) 2(3):125–128. doi:10.1111/j.1365-2354.1993.tb00181.x CrossRef

11.

Ridner SH, Bonner CM, Deng J, Sinclair VG (2012) Voices From the Shadows: Living with lymphedema. Cancer Nurs 35(1):E18–E26. doi:10.1097/NCC.0b013e31821404c0 PubMedCentralCrossRefPubMed

12.

Ridner SH, Sinclair V, Deng J, Bonner CM, Kidd N, Dietrich MS (2012) Breast Cancer Survivors with Lymphedema: Glimpses of their daily lives. Clin J Oncol Nurs 16(6):609–614. doi:10.1188/12.CJON. 609-614 CrossRefPubMed

13.

Armer JM, Radina ME, Porock D, Culbertson SD (2003) Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 52(6):370–379CrossRefPubMed

14.

Brown JC, Kumar A, Cheville AL, Tchou JC, Troxel AB, Harris SR, Schmitz KH (2014) Association between lymphedema self-care adherence and lymphedema outcomes among women with breast cancer-related lymphedema. Am J Phys Med Rehabil. doi:10.1097/PHM.0000000000000178

15.

Norman SA, Miller LT, Erikson HB, Norman MF, McCorkle R (2001) Development and validation of a telephone questionnaire to characterize lymphedema in women treated for breast cancer. Phys Ther 81(6):1192–1205PubMed

16.

Coster S, Poole K, Fallowfield LJ (2001) The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively. Breast Cancer Res Treat 68(3):273–282CrossRefPubMed

17.

Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F (1997) The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci 19(3):14–27CrossRefPubMed

18.

Lenz ER, Suppe F, Gift AG, Pugh LC, Milligan RA (1995) Collaborative development of middle-range nursing theories: toward a theory of unpleasant symptoms. ANS Adv Nurs Sci 17(3):1–13CrossRefPubMed

19.

Ridner SH, Murphy B, Deng J, Kidd N, Galford E, Bonner C, Bond SM, Dietrich MS (2012) A randomized clinical trial comparing advanced pneumatic truncal, chest, and arm treatment to arm treatment only in self-care of arm lymphedema. Breast Cancer Res Treat 131(1):147–158. doi:10.1007/s10549-011-1795-5 CrossRefPubMed

20.

Ridner SH, Poage-Hooper E, Kanar C, Doersam JK, Bond SM, Dietrich MS (2013) A pilot randomized trial evaluating low-level laser therapy as an alternative treatment to manual lymphatic drainage for breast cancer-related lymphedema. Oncol Nurs Forum 40(4):383–393. doi:10.1188/13.ONF. 383-393 CrossRefPubMed

21.

Cella D (1997) FACIT Manual: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Center on Outcomes, Research and Education

22.

Launois R, Mègnigbêto A, Le Lay K, Alliot F (2001) CN5: A Specific Quality Of Life Scale In Upper Limb Lymphoedema: The Ull-27 Questionnaire. Value Health 4(6):407–408CrossRef

23.

Seltzer GB, Granger CV, Wineberg DE (1982) Functional Assessment: Bridge between family and rehabilitation medicine within an ambulatory practice. Arch Phys Med Rehabil 63(10):453PubMed

24.

Millard RW (1989) The Functional Assessment Screening Questionnaire: Application for evaluating pain-related disability. Arch Phys Med Rehabil 70(4):303–307PubMed

25.

Radloff LS (1977) The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1(3):385CrossRef

26.

Curran SL, Andrykowski MA, Studts JL (1995) Short form of the Profile of Mood States (POMS-SF): Psychometric information. Psychol Assess 7(1):80–83CrossRef

27.

Shacham S (1983) A shortened version of the Profile of Mood States. J Pers Assess 47(3):305–306CrossRefPubMed

28.

Crowne DP, Marlowe D (1960) A new scale of social desirability independent of psychopathology. J Consult Psychol 24(4):349–354CrossRefPubMed

29.

Goldfried MR (1964) A cross-validation of the Marlowe-Crowne Social Desirability Scale items. J Soc Psychol 64(1):137–145CrossRefPubMed

Title: Development and validation of the Lymphedema Symptom and Intensity Survey-Arm
Authors: Sheila H. Ridner
Mary S. Dietrich
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 10/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2684-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis

Lymphoedema and health-related quality of life by early treatment in long-term survivors of breast cancer. A comparative retrospective study up to 15 years after diagnosis

Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile

Cognitive impairment in testicular cancer survivors 2 to 7 years after treatment

Exercise compliance among patients with multiple myeloma undergoing chemotherapy: a retrospective study

Outcomes from treating bile acid malabsorption using a multidisciplinary approach

Keynote webinar | Spotlight on antibody–drug conjugates in cancer